IMMUNCIN™ Vaxil’s Lead Immunotherapy

In a Phase I/II clinical study involving 15 MM patients, ImMucin induced a strong and specific response of both CD4+ and CD8+ T-cells in all patients, coupled with an antibody response in ~66% (10/15) of the patients.

Moreover, as anticipated, ImMucin was able to cause this in patients with vastly different immune repertoires with no need for prior patient selection based on their immune MHC typing. Importantly, 9 out of 10 patients having abnormal soluble MUC1 blood levels prior to ImMucin therapy experienced a significant reduction in soluble MUC1. Reduction in the % of plasma cells in the bone marrow and other accepted measures such as M-protein and FLC was demonstrated post treatment in certain patients.

Lastly, stable disease or improvement, persisting for 17.5-41.3 months (on-going) was achieved in 11/15 patients and appeared to be associated with low-intermediate PDL1 (CD274) bone marrow levels pre- and post-ImMucin treatment. Vaxil’s trial was published in the British Journal of Haematology.

VAXIL – Creating the ideal immunotherapy

Inducing a Broad

Response

Learn More

universally

Applicable

Learn More

Overcoming

Cancer Resistance

Learn More

Harnessing Potent

Immune Response

Learn More

Tumor

Specific

Learn More

Expression on

Cancer Stem Cells

Learn More

neo-antigen

acting

Learn More

First Ever SP-Specific

Antibody Platform

Learn More

Vaxil’s Lead Products and Orphan Drug Status

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is ​its ImMucin™ ​lead immunotherapy product.